[go: up one dir, main page]

NO20054006D0 - Cyclic urea derivatives, their preparation process and the pharmaceutical use of the same as kinase inhibitors - Google Patents

Cyclic urea derivatives, their preparation process and the pharmaceutical use of the same as kinase inhibitors

Info

Publication number
NO20054006D0
NO20054006D0 NO20054006A NO20054006A NO20054006D0 NO 20054006 D0 NO20054006 D0 NO 20054006D0 NO 20054006 A NO20054006 A NO 20054006A NO 20054006 A NO20054006 A NO 20054006A NO 20054006 D0 NO20054006 D0 NO 20054006D0
Authority
NO
Norway
Prior art keywords
same
preparation process
kinase inhibitors
pharmaceutical use
urea derivatives
Prior art date
Application number
NO20054006A
Other languages
Norwegian (no)
Other versions
NO20054006L (en
Inventor
Jean-Luc Malleron
Augustin Hittinger
Jacques Mauger
Herve Bouchard
Hartmut Strobel
Youssef El-Ahmad
Fahad A D Al-Obeidi
Conception Nemecek
Thomas H Faitg
Marcel Patek
Anil Nair
Daniel Bond
Greg Harlow
Mark Palermo
Sven Ruf
Kurt Ritter
Dominique Lesuisse
Didier Benard
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20054006D0 publication Critical patent/NO20054006D0/en
Publication of NO20054006L publication Critical patent/NO20054006L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20054006A 2003-01-31 2005-08-29 Cyclic urea derivatives, their preparation process and the pharmaceutical use of the same as kinase inhibitors NO20054006L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0301098A FR2850652B1 (en) 2003-01-31 2003-01-31 NOVEL CYCLIC UREA DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES
PCT/FR2004/000188 WO2004070050A2 (en) 2003-01-31 2004-01-28 Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors

Publications (2)

Publication Number Publication Date
NO20054006D0 true NO20054006D0 (en) 2005-08-29
NO20054006L NO20054006L (en) 2005-10-13

Family

ID=32696243

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054006A NO20054006L (en) 2003-01-31 2005-08-29 Cyclic urea derivatives, their preparation process and the pharmaceutical use of the same as kinase inhibitors

Country Status (24)

Country Link
EP (1) EP1599464B1 (en)
JP (1) JP4604020B2 (en)
KR (1) KR20050098286A (en)
CN (1) CN1768054A (en)
AR (1) AR042936A1 (en)
AT (1) ATE482207T1 (en)
AU (1) AU2004209319A1 (en)
BR (1) BRPI0407091A (en)
CA (1) CA2513631A1 (en)
DE (1) DE602004029236D1 (en)
FR (1) FR2850652B1 (en)
HR (1) HRP20050679A2 (en)
MA (1) MA27651A1 (en)
ME (1) MEP22608A (en)
MX (1) MXPA05007407A (en)
NO (1) NO20054006L (en)
NZ (1) NZ541270A (en)
PE (1) PE20040808A1 (en)
PL (1) PL377811A1 (en)
RS (1) RS20050657A (en)
RU (1) RU2341523C2 (en)
TW (1) TW200505898A (en)
WO (1) WO2004070050A2 (en)
ZA (1) ZA200505934B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2536622C (en) 2003-08-29 2014-02-11 The Brigham And Women's Hospital, Inc. Inhibitors of cellular necrosis
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
DE602004031881D1 (en) 2003-12-19 2011-04-28 Univ California METHOD AND MATERIALS FOR ASSESSING PROSTATE ACID THERAPIES
WO2005099693A2 (en) 2004-02-24 2005-10-27 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
EP1621536A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621535A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
KR101782236B1 (en) 2005-05-13 2017-09-26 더 리전트 오브 더 유니버시티 오브 캘리포니아 Diarylhydantoin compounds
US7709516B2 (en) * 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
FR2896504B1 (en) * 2006-01-23 2012-07-13 Aventis Pharma Sa NOVEL CYCLIC UREA DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES
FR2896503B1 (en) * 2006-01-23 2012-07-13 Aventis Pharma Sa NOVEL CYCLIC UREA SULFUR DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES
PT2368550E (en) 2006-03-27 2013-12-03 Univ California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
CN101460467B (en) 2006-03-29 2012-09-19 加利福尼亚大学董事会 Diarylthiohydantoins
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
AU2007332754A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors
UY31432A1 (en) 2007-10-26 2009-05-29 DIARILHIDANTOINE COMPOUNDS
AU2009329879A1 (en) 2008-12-23 2011-08-11 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
EA028869B1 (en) 2010-02-16 2018-01-31 Арагон Фармасьютикалс, Инк. Androgen receptor modulators and use thereof
WO2012087862A2 (en) * 2010-12-21 2012-06-28 Cytec Technology Corp. Microdispersions of hydroxamated polymers and methods of making and using them
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
MY180834A (en) 2012-09-26 2020-12-10 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (en) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
GB201312492D0 (en) * 2013-07-12 2013-08-28 Syngenta Ltd Herbicidal compounds
WO2015108861A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US10202373B2 (en) 2014-01-14 2019-02-12 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
AR102981A1 (en) 2014-12-11 2017-04-05 Harvard College INHIBITORS OF CELL NECROSIS AND METHODS OF PREPARATION OF THE SAME
TWI726969B (en) 2016-01-11 2021-05-11 比利時商健生藥品公司 Substituted thiohydantoin derivatives as androgen receptor antagonists
CN107619388A (en) * 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 Heterocyclic compound as FGFR inhibitor
PT3971177T (en) * 2016-07-20 2024-07-30 Novartis Ag Aminopyridine derivatives and their use as selective alk-2 inhibitors
MX2020003845A (en) 2017-10-16 2020-11-06 Aragon Pharmaceuticals Inc ANTIANDROGENS FOR THE TREATMENT OF NON-METASTATIC PROSTATE CANCER RESISTANT TO CASTRATION.
AU2018358582B2 (en) * 2017-10-31 2021-06-10 Pelemed Co., Ltd. Pharmaceutical composition for prevention or treatment of acute myeloid leukemia or metastatic breast cancer
TW202517640A (en) * 2023-07-18 2025-05-01 愛爾蘭商赫瑞森治療學愛爾蘭指定活動公司 Heterocyclic inhibitors of igf-1r for treatment of disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2329276A1 (en) * 1975-10-29 1977-05-27 Roussel Uclaf NEW SUBSTITUTES IMIDAZOLIDINES, METHOD OF PREPARATION, APPLICATION AS A MEDICINAL PRODUCT AND COMPOSITIONS CONTAINING THEM
DE4228717A1 (en) * 1992-08-28 1994-03-03 Cassella Ag Imidazolidine derivatives
DE19540027A1 (en) * 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituted imidazolidine-2,4-dione compounds as active pharmaceutical ingredients
SK117499A3 (en) * 1997-03-03 2000-05-16 Boehringer Ingelheim Pharma Small molecules useful in the treatment of inflammatory and immune cell-mediated diseases, small molecules and pharmaceutical composition with their content
DE19732928C2 (en) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Use of substituted imidazolidine-2,4-dione compounds as pain relievers
FR2796945B1 (en) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic NOVEL DERIVATIVES OF HYDANTOINS, THIOHYDANTOINS, PYRIMIDINEDIONES AND THIOXOPYRIMIDINONES, PROCESSES FOR THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS
ES2284641T3 (en) * 2000-05-31 2007-11-16 Tanabe Seiyaku Co., Ltd. INHIBITORS OF CELLULAR ADHESION MEDIATED BY ALFA-L-BETA-2.
IL165218A0 (en) * 2002-05-16 2005-12-18 Bayer Cropscience Gmbh Pyridine carboxamide derivatives and their use as pesticides

Also Published As

Publication number Publication date
RU2005127335A (en) 2006-09-10
ATE482207T1 (en) 2010-10-15
NZ541270A (en) 2008-11-28
CN1768054A (en) 2006-05-03
FR2850652B1 (en) 2008-05-30
MA27651A1 (en) 2005-12-01
CA2513631A1 (en) 2004-08-19
ZA200505934B (en) 2007-06-27
JP2006517569A (en) 2006-07-27
NO20054006L (en) 2005-10-13
EP1599464A2 (en) 2005-11-30
MXPA05007407A (en) 2005-09-12
FR2850652A1 (en) 2004-08-06
PE20040808A1 (en) 2004-12-31
RU2341523C2 (en) 2008-12-20
DE602004029236D1 (en) 2010-11-04
WO2004070050A3 (en) 2005-02-17
PL377811A1 (en) 2006-02-20
EP1599464B1 (en) 2010-09-22
JP4604020B2 (en) 2010-12-22
BRPI0407091A (en) 2006-01-24
KR20050098286A (en) 2005-10-11
AU2004209319A1 (en) 2004-08-19
RS20050657A (en) 2007-06-04
WO2004070050A2 (en) 2004-08-19
TW200505898A (en) 2005-02-16
HRP20050679A2 (en) 2006-12-31
MEP22608A (en) 2010-06-10
AR042936A1 (en) 2005-07-06

Similar Documents

Publication Publication Date Title
NO20054006D0 (en) Cyclic urea derivatives, their preparation process and the pharmaceutical use of the same as kinase inhibitors
IL180488A0 (en) Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof of kinase inhibitors
IL180286A0 (en) Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
IL180257A0 (en) Heterocycle-substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
NO20054905D0 (en) 2-acylamino-4-phenylthiazole derivatives, processes for their preparation and use of the same as in therapeutics
NO20034187L (en) Novel spirotric cyclic derivatives and their use as phosphodiesterase-7 inhibitors
IS7543A (en) Benzothiadiazepine derivatives, methods of their manufacture and pharmaceutical compositions containing them
NO20053356L (en) Aminindazole derivatives and their use as kinase inhibitors.
AP2064A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
DK1368349T3 (en) Xanthine derivatives, their preparation and their use as pharmaceuticals
NO20054244D0 (en) Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
EE200300327A (en) Urea derivatives, processes for their preparation, use and pharmaceutical composition
EE200300581A (en) Carboxamide-substituted phenylurea derivatives and their use, drug and process for its preparation
IL192440A0 (en) Sulphur-containing cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
NO20055204D0 (en) Derivatives of piperidinyl and pipemzinylalkylcarbamates, processes for their preparation and their use in therapy
CY2017048I1 (en) NEW PHARMACEUTICAL USES OF STAVROSPORINE DERIVATIVES
DK1670458T3 (en) 1-Amino-2-oxy-substituted tetrahydronaphthalane derivatives, processes for their preparation and their use as antiphlogistics
IL192442A0 (en) Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
DK1500654T3 (en) Benzoxazinone derivatives, their preparation and their use as pharmaceuticals
IL182054A0 (en) Novel bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors
IL179758A0 (en) Substituted tetrahydro - 2h - isoquinolin - 1 - one derivatives, method for the production thereof, and use of the same as medicaments
IS8422A (en) Benzimidazole derivatives, preparations containing them, their preparation and their use
NO20054876D0 (en) Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as drug and drug containing such compounds
IS8219A (en) Benzimidazole derivatives, preparations containing them, their preparation and use
IS7424A (en) Oxazolidinone derivatives, methods of preparing them and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application